European Journal of Surgical Oncology
Volume 38, Issue 2 , Pages 110-117 , February 2012

High non-compliance in the use of letrozole after 2.5years of extended adjuvant endocrine therapy. Results from the IDEAL randomized trial

  • D.B.Y. Fontein

      Affiliations

    • Department of Surgical Oncology, Leiden University Medical Centre, Albinusdreef 2, 2333ZA Leiden, The Netherlands
    • Corresponding Author InformationCorresponding author. Tel.: +31 71 526 3500; fax: +31 71 526 6744.
    • ,
  • J.W.R. Nortier

      Affiliations

    • Department of Medical Oncology, Leiden University Medical Centre, Albinusdreef 2, 2333ZA Leiden, The Netherlands
    • ,
  • G.J. Liefers

      Affiliations

    • Department of Surgical Oncology, Leiden University Medical Centre, Albinusdreef 2, 2333ZA Leiden, The Netherlands
    • ,
  • H. Putter

      Affiliations

    • Department of Medical Statistics, Leiden University Medical Centre, Albinusdreef 2, 2333ZA Leiden, The Netherlands
    • ,
  • E. Meershoek-Klein Kranenbarg

      Affiliations

    • Department of Surgical Oncology, Leiden University Medical Centre, Albinusdreef 2, 2333ZA Leiden, The Netherlands
    • ,
  • J. van den Bosch

      Affiliations

    • Department of Medical Oncology, Albert Schweitzer Hospital, P.O. Box 444, 3300AK Dordrecht, The Netherlands
    • ,
  • E. Maartense

      Affiliations

    • Department of Medical Oncology, Reinier de Graaf Hospital, P.O. Box 5011, 2600GA Delft, The Netherlands
    • ,
  • E.J.Th. Rutgers

      Affiliations

    • Department of Surgery, The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066CX Amsterdam, The Netherlands
    • ,
  • C.J.H. van de Velde

      Affiliations

    • Department of Surgical Oncology, Leiden University Medical Centre, Albinusdreef 2, 2333ZA Leiden, The Netherlands

,Accepted 21 November 2011.

References 

  1. Goss PE. Emerging role of aromatase inhibitors in the adjuvant setting. Am J Clin Oncol. 2003;26(4):S27–S33
  2. Howell A, Cuzick J, Baum M, et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet. 2005;365(9453):60–62
  3. Kaufmann M, Jonat W, Hilfrich J, et al. Improved overall survival in postmenopausal women with early breast cancer after anastrozole initiated after treatment with tamoxifen compared with continued tamoxifen: the ARNO 95 Study. J Clin Oncol. 2007;25(19):2664–2670
  4. Thurlimann B, Keshaviah A, Coates AS, et al. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med. 2005;353(26):2747–2757
  5. van de Velde CJ, Rea D, Seynaeve C, et al. Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase 3 trial. Lancet. 2011;377(9762):321–331
  6. Goss PE, Ingle JN, Martino S, et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med. 2003;349(19):1793–1802
  7. Hadji P. Improving compliance and persistence to adjuvant tamoxifen and aromatase inhibitor therapy. Crit Rev Oncol Hematol. 2010;73(2):156–166
  8. Partridge AH. Non-adherence to endocrine therapy for breast cancer. Ann Oncol. 2006;17(2):183–184
  9. Barron TI, Connolly R, Bennett K, Feely J, Kennedy MJ. Early discontinuation of tamoxifen: a lesson for oncologists. Cancer. 2007;109(5):832–839
  10. Chlebowski RT, Geller ML. Adherence to endocrine therapy for breast cancer. Oncology. 2006;71(1–2):1–9
  11. Hershman DL, Shao T, Kushi LH, et al. Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer. Breast Cancer Res Treat. 2011;126(2):529–537
  12. Ziller V, Kalder M, Albert US, et al. Adherence to adjuvant endocrine therapy in postmenopausal women with breast cancer. Ann Oncol. 2009;20(3):431–436
  13. Smith IE, Dowsett M. Aromatase inhibitors in breast cancer. N Engl J Med. 2003;348(24):2431–2442
  14. Burstein HJ. Aromatase inhibitor-associated arthralgia syndrome. Breast. 2007;16(3):223–234
  15. Loibl S, Lintermans A, Dieudonne AS, Neven P. Management of menopausal symptoms in breast cancer patients. Maturitas. 2011;68(2):148–154
  16. Geisler J. Differences between the non-steroidal aromatase inhibitors anastrozole and letrozole–of clinical importance?. Br J Cancer. 2011;104(7):1059–1066
  17. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365(9472):1687–1717
  18. Fink AK, Gurwitz J, Rakowski W, Guadagnoli E, Silliman RA. Patient beliefs and tamoxifen discontinuance in older women with estrogen receptor–positive breast cancer. J Clin Oncol. 2004;22(16):3309–3315
  19. Partridge AH, Wang PS, Winer EP, Avorn J. Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer. J Clin Oncol. 2003;21(4):602–606
  20. Grunfeld EA, Hunter MS, Sikka P, Mittal S. Adherence beliefs among breast cancer patients taking tamoxifen. Patient Educ Couns. 2005;59(1):97–102
  21. Muss HB, Tu D, Ingle JN, et al. Efficacy, toxicity, and quality of life in older women with early-stage breast cancer treated with letrozole or placebo after 5 years of tamoxifen: NCIC CTG Intergroup trial MA.17. J Clin Oncol. 2008;26(12):1956–1964
  22. Owusu C, Buist DS, Field TS, et al. Predictors of tamoxifen discontinuation among older women with estrogen receptor-positive breast cancer. J Clin Oncol. 2008;26(4):549–555
  23. Balkrishnan R. Predictors of medication adherence in the elderly. Clin Ther. 1998;20(4):764–771
  24. Jatoi I, Proschan MA. Randomized trials of breast-conserving therapy versus mastectomy for primary breast cancer: a pooled analysis of updated results. Am J Clin Oncol. 2005;28(3):289–294
  25. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353(5):487–497
  26. Ruddy K, Mayer E, Partridge A. Patient adherence and persistence with oral anticancer treatment. CA Cancer J Clin. 2009;59(1):56–66
  27. Dezentje VO, Guchelaar HJ, Nortier JW, van de Velde CJ, Gelderblom H. Clinical implications of CYP2D6 genotyping in tamoxifen treatment for breast cancer. Clin Cancer Res. 2009;15(1):15–21
  28. Goetz MP, Knox SK, Suman VJ, et al. The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. Breast Cancer Res Treat. 2007;101(1):113–121
  29. Brauch H, Schroth W, Eichelbaum M, Schwab M, Harbeck N. Clinical relevance of CYP2D6 genetics for tamoxifen response in breast cancer. Breast Care (Basel). 2008;3(1):43–50

PII: S0748-7983(11)00698-6

doi: 10.1016/j.ejso.2011.11.010

European Journal of Surgical Oncology
Volume 38, Issue 2 , Pages 110-117 , February 2012

Article Tools

* Image Usage & Resolution